CR20220558A - Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso - Google Patents

Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso

Info

Publication number
CR20220558A
CR20220558A CR20220558A CR20220558A CR20220558A CR 20220558 A CR20220558 A CR 20220558A CR 20220558 A CR20220558 A CR 20220558A CR 20220558 A CR20220558 A CR 20220558A CR 20220558 A CR20220558 A CR 20220558A
Authority
CR
Costa Rica
Prior art keywords
compounds
methods
pharmaceutical compositions
disclosed
preparing
Prior art date
Application number
CR20220558A
Other languages
English (en)
Inventor
Janek Szychowski
Bingcan Liu
Jean-François Truchon
Robert Papp
Evelyne Dietrich
Frédéric Vallée
Alexander Perryman
Patrick Beaulieu
Original Assignee
Repare Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repare Therapeutics Inc filed Critical Repare Therapeutics Inc
Publication of CR20220558A publication Critical patent/CR20220558A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describen compuestos y sales farmacéuticamente aceptables de estos que se pueden usar en el tratamiento de sujetos que los necesitan. Los compuestos descritos en el presente documento pueden ser inhibidores de la cinasa inhibidora de cdc2 específica de treonina y tirosina (Myt1). 5 También se describen composiciones farmacéuticas que contienen los compuestos o sales farmacéuticamente aceptables de estos y métodos para su preparación y uso.
CR20220558A 2020-04-01 2021-04-01 Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso CR20220558A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063003745P 2020-04-01 2020-04-01
PCT/CA2021/050443 WO2021195781A1 (en) 2020-04-01 2021-04-01 Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use

Publications (1)

Publication Number Publication Date
CR20220558A true CR20220558A (es) 2022-12-12

Family

ID=77927736

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220558A CR20220558A (es) 2020-04-01 2021-04-01 Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso

Country Status (14)

Country Link
US (1) US20230151014A1 (es)
EP (1) EP4126879A4 (es)
JP (1) JP2023521633A (es)
KR (1) KR20230011279A (es)
CN (1) CN115916783A (es)
AU (1) AU2021250744A1 (es)
BR (1) BR112022019611A2 (es)
CA (1) CA3177200A1 (es)
CO (1) CO2022015638A2 (es)
CR (1) CR20220558A (es)
EC (1) ECSP22083904A (es)
IL (1) IL296934A (es)
MX (1) MX2022012178A (es)
WO (1) WO2021195781A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021195782A1 (en) * 2020-04-01 2021-10-07 Repare Therapeutics Inc. Methods of using myt1 inhibitors
WO2022072512A1 (en) * 2020-09-30 2022-04-07 Metacrine, Inc. Hsd17b13 inhibitors and uses thereof
CN117729920A (zh) * 2021-04-07 2024-03-19 修复治疗公司 可用作myt1抑制剂的甲酰胺吡咯并吡嗪和吡啶化合物及其在治疗癌症中的用途
WO2023155892A1 (en) * 2022-02-18 2023-08-24 Insilico Medicine Ip Limited Membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
WO2023155870A1 (en) * 2022-02-18 2023-08-24 Insilico Medicine Ip Limited Membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
WO2023174329A1 (en) * 2022-03-15 2023-09-21 Insilico Medicine Ip Limited Heteroaromatic compounds as pkmyt1 inhibitors and use thereof
WO2023198199A1 (zh) * 2022-04-15 2023-10-19 先声再明医药有限公司 膜缔合酪氨酸和苏氨酸激酶抑制剂
WO2023220831A1 (en) * 2022-05-18 2023-11-23 Repare Therapeutics Inc. Heteroarenes, pharmaceutical compositions containing the same, and methods of using the same
WO2023249563A1 (en) * 2022-06-23 2023-12-28 Engine Biosciences Pte. Ltd. Compounds and method for pkmyt1 inhibition
WO2024012409A1 (zh) * 2022-07-12 2024-01-18 微境生物医药科技(上海)有限公司 作为myt1抑制剂的化合物
WO2024041440A1 (en) * 2022-08-24 2024-02-29 Danatlas Pharmaceuticals Co., Ltd. Tricyclic heterocyclic derivatives, compositions and uses thereof
WO2024048687A1 (ja) * 2022-08-31 2024-03-07 中外製薬株式会社 Ｍｙｔ１阻害剤と化学療法剤を併用する、ｒｂ１の機能低下が生じている患者のがんの治療剤及び治療方法
WO2024061343A1 (zh) * 2022-09-23 2024-03-28 先声再明医药有限公司 膜缔合酪氨酸和苏氨酸激酶抑制剂及其应用
WO2024104282A1 (zh) * 2022-11-14 2024-05-23 捷思英达控股有限公司 一种1H-吡咯并[2,3-b]吡啶衍生物、其制备方法及其在医药上的应用
WO2024109942A1 (zh) * 2022-11-25 2024-05-30 上海齐鲁制药研究中心有限公司 Pkmyt1抑制剂、制备方法、药物组合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1137415A4 (en) * 1998-12-07 2002-03-20 Smithkline Beecham Corp MYT1 KINASE INHIBITORS
CO5261594A1 (es) * 2000-03-02 2003-03-31 Smithkline Beecham Corp Inhibidores de myt1 cinasa
WO2015073528A1 (en) * 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
EP3194392B1 (en) * 2014-09-15 2020-01-01 Plexxikon, Inc. Heterocyclic compounds and uses thereof

Also Published As

Publication number Publication date
MX2022012178A (es) 2022-12-08
US20230151014A1 (en) 2023-05-18
WO2021195781A1 (en) 2021-10-07
AU2021250744A1 (en) 2022-11-17
ECSP22083904A (es) 2022-11-30
JP2023521633A (ja) 2023-05-25
CO2022015638A2 (es) 2022-11-18
CN115916783A (zh) 2023-04-04
BR112022019611A2 (pt) 2022-11-29
KR20230011279A (ko) 2023-01-20
EP4126879A4 (en) 2024-04-10
EP4126879A1 (en) 2023-02-08
IL296934A (en) 2022-12-01
CA3177200A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
MX2022012178A (es) Compuestos, composiciones farmaceuticas y metodos para la preparacion de compuestos y para su uso.
PH12021550992A1 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
CR20200064A (es) Carboxamidas como moduladores de los canales de sodio
MX2022006865A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
EA202092320A1 (ru) Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
IL260127B (en) mek inhibitors and methods of using them
MX2022004937A (es) Inhibidores de las cinasas raf.
WO2021195782A8 (en) Methods of using myt1 inhibitors
MX2021003517A (es) Composiciones de inhibidor de tirosina quinasa, metodos de fabricacion y metodos de uso.
MX2017013142A (es) Terapia combinada para tratar cáncer.
ME00142B (me) Derivati pirazolo-hinazolina, postupci za njihovo dobijanje i njihova upotreba kao inhibitora kinaze
GEP20094845B (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
CL2008002243A1 (es) Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
MX2021014455A (es) Inhibidores de proteina cinasas dependientes de adn.
WO2016109217A3 (en) Btk inhibitors
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
MX2022005749A (es) Inhibidores de egfr alostericos y metodos de uso de los mismos.
MX2022015410A (es) Inhibidores de las cinasas receptoras del factor de crecimiento de fibroblastos.
MX2023002553A (es) Compuestos de quinolina antagonistas del cgas.
JOP20200015A1 (ar) توليفة علاجية من مثبط كيناز تيروسين egfr من الجيل الثالث ومثبط كيناز يعتمد على سيكلين
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
MX2022015739A (es) Inhibidores alostericos de egfr y metodos de uso de estos.